Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK201 and Ivonescimab in Advanced Squamous Non-Small Cell Lung Cancer
NCT07742956Phase 2Not yet recruiting
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of ALK201 in squamous cell carcinoma of the lung (SCCL), sponsored by Shanghai Allink Biotherapeutics Co., Ltd.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ALK201
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07742956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742956.